Impact of pharmacogenetics on aspirin resistance: a systematic review

Silva, Gustavo Figueiredo da; Lopes, Bruno Mattei; Moser, Vinicius; Ferreira, Leslie Ecker

doi:10.1055/s-0042-1758445

Cited by 2 publications

(1 citation statement)

References 27 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Individual responses to aspirin may be determined by genetic, physiological, and environmental factors. For instance, variations in genes involved in drug metabolism (such as cytochrome P450 enzymes 57 ) can impact the rate of aspirin metabolism, while polymorphisms in genes related to platelet function and coagulation (such as COX‐1 and GP1BA 58 ) may affect the efficacy of aspirin in inhibiting platelet aggregation. Therefore, healthcare providers should consider these genetic and physiological factors when devising personalized aspirin dosing regimens to balance treatment effectiveness and safety.…”

Section: Discussionmentioning

confidence: 99%

The optimal dosage of aspirin for preventing preeclampsia in high‐risk pregnant women: A network meta‐analysis of 23 randomized controlled trials

Hu,

Chen,

Wang

et al. 2024

J of Clinical Hypertension

View full text Add to dashboard Cite

This study aimed to assess the effectiveness and optimal dosage of aspirin in preventing preeclampsia in high‐risk pregnant women. Traditional and network meta‐analyses were conducted on data from 23 randomized controlled trials involving 10 547 pregnant women. The findings demonstrated that aspirin significantly reduced the incidence of preeclampsia (OR = 0.66, 95%CI [0.58, 0.75]), with the best preventive effect observed at a dosage of 80–100 mg/day (OR = 0.51, 95%CI [0.36, 0.72]). No significant differences were found in the occurrence of postpartum hemorrhage (OR = 1.03, 95%CI [0.79, 1.33]), small for gestational age (OR = 0.83, 95%CI [0.50, 1.35]), placental abruption (OR = 0.96, 95%CI [0.53, 1.73]), and intrauterine growth restriction (OR = 0.63, 95%CI [0.45, 1.86]) between women taking aspirin and those taking placebos. Different doses of aspirin showed a reduction in preeclampsia incidence, but there was no significant difference in efficacy between the dosage groups. Side effects did not significantly differ between placebo and different aspirin dosage groups. SUCRA analysis suggested that 80–100 mg/day may be the optimal dosage, prioritizing both effectiveness and minimizing side effects. Sensitivity analysis confirmed the robustness of the findings. However, improvements are needed in addressing issues like loss to follow‐up, reporting bias, and publication bias. In conclusion, a dosage of 80–100 mg/day is recommended for preventing preeclampsia in high‐risk pregnant women, although individual circumstances should be considered for optimizing the balance between effectiveness and safety.

show abstract

Section: Discussionmentioning

confidence: 99%

The optimal dosage of aspirin for preventing preeclampsia in high‐risk pregnant women: A network meta‐analysis of 23 randomized controlled trials

Hu,

Chen,

Wang

et al. 2024

J of Clinical Hypertension

View full text Add to dashboard Cite

show abstract

Genetics in the diagnosis and treatment of cardiovascular diseases

Bliden,

Singh,

Shanoada

et al. 2024

J Transl Genet Genom

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) remain one of the leading causes of morbidity and mortality worldwide, with genetics being a major risk factor. Genetic cardiovascular disease can occur either because of single variant (Mendelian) or polygenic influences and has been linked to inherited cardiovascular conditions (ICC) such as arrhythmias, cardiomyopathies, dyslipidemias, and aortopathies which are significant factors leading to sudden cardiac death in young adults. Timely screening, diagnosis, and management of ICC can not only provide life-saving treatment to a patient, but also identify at-risk family members. The field of pharmacogenomics (PGx) helped to understand the variable action of medications such as clopidogrel, aspirin, warfarin, and statin according to genotype. Newer technologies such as multi-omics can combine data from multiple sources such as genomics, epigenomics, transcriptomics, proteomics, metabolomics, and microbiome. These advancements can contribute to the development of polygenic prediction scores and precision medicine tailored to individual genotypes. Substantial strides have been made in genetic-based therapeutics, gene editing technologies, and drug delivery systems, which have significantly expanded treatment options for patients with acquired or inherited CVDs. Although variable, the country- and society-specific guidelines on genetic testing for ICC and PGx and treatment are being continuously updated to keep up with ongoing research in the field. Along with appropriate knowledge, other factors including cost and availability of genetic testing play a vital role in the usage by both physicians and patients. With the advent of newer genetic testing for CVDs, a key factor is the availability of genetic counselors (GCs) who are specifically trained in cardiovascular genomics. The current review provides a concise summary of the major influences of genetics in the diagnosis and treatment of CVDs.

show abstract

Impact of pharmacogenetics on aspirin resistance: a systematic review

Cited by 2 publications

References 27 publications

The optimal dosage of aspirin for preventing preeclampsia in high‐risk pregnant women: A network meta‐analysis of 23 randomized controlled trials

The optimal dosage of aspirin for preventing preeclampsia in high‐risk pregnant women: A network meta‐analysis of 23 randomized controlled trials

Genetics in the diagnosis and treatment of cardiovascular diseases

Contact Info

Product

Resources

About